Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A receptors

Daru

Volumn 18, Issue 1, 2010, Pages 42-45

  Mohajjel Nayebi, A ^a   Sheidaei, H ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5 HT1A receptors; Buspirone; Haloperidol; Motor dysfunction

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; BUSPIRONE; HALOPERIDOL; PARTIAL AGONIST; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BALANCE DISORDER; CATALEPSY; DOSE RESPONSE; DRUG INDUCED DISEASE; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; ROTAROD TEST; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77949690052     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Scholtissen B, Verhey FRJ, Steinbusch HWM, Leentjens AFG. Serotonergic mechnisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm, 2006; 113: 59-73.
2. Miyawaki E, Meah Y, Koller WC. Serotonin, dopamine, and motor effects in parkinson's disease. Clin Neuropharmacol, 1997; 20: 300-310.
3. Chase TN. Serotonergic mechanisms and extrapyramidal function in man. Adv Neurol, 1974; 5: 31-39.
4. De Deurwaerdere P, Navailles S, Berg KA, Clark WP, Spampinato U. Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci, 2004; 24: 3235-3241.
5. Benloucif S, Keegan MJ, Galloway MP. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther, 1993; 265: 373-377.
6. Navailles S, De Deurwaerdere P, Porras G, Spampinato U. In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology, 2004; 29: 319-326.
7. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, Noda T, Satomi M, Ohtaki K, Chiba K, Tasaki Y, Shiono H. Tandospirone 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res, 2006; 1112: 126-133.
8. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res, 2007; 1158: 135-143.
9. Schechter LE, Bolaños FJ, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte AM, Fattaccini CM, Hamon M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther, 1990; 255: 1335-1347.
10. Arborelius L, Chergui K, Murase S, Nomikos GG, Hook BB, Chouvet G, Hacksell U, Svensso Arborelius L, Chergui K, Murase S, Nomikos GG, Hook BB, Chouvet G, Hacksell U, Svensson TH. n TH. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopemine neurons. Naunyn Schmiedebergs Arch Pharmacol, 1993; 347: 353-362.
11. Ichikawa J, Meltzer HY. R(+)-8-OH-DPAT, a serotonin1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther, 1999; 291: 1227-1232.
12. Lucas G, Bonhomme N, De Deurwaerdere P, Le Moal M, Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol induced catalepsy in rats independently of striatal dopamine release. Psychpharmacology, 1997; 131: 57-63.
13. Wang S, Hu LF, Yang Y, Ding JH, HU G. Studies of ATP-seneitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson>s disease: Implications for treating Parkinson >s disease? Neuropharmacology, 2005; 48: 984-992.
14. Pires JG, Costa PG, Saraiva FP, Bonikovski V, Futuro Neto HA. Gender-related differences in the effects of nitric oxide donors on neuroleptic induced catalepsy in mice. Braz J Med Biol Res, 2003; 36: 239-245.
15. Pires JG, Bonikoski V, Futuro-Neto HA. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res, 2005; 38: 1867-1872.
16. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma, 1994; 11: 187-196.
17. Nayebi A, Nazemiyeh H. Omidbakhsh R, Çobanoglu S: Analgesic effect of the methanol extract of Erica arborea (L.) in mice using formalin test. Daru, 2008; 16: 229-232.
18. 1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl), 2007; 192: 49-59.
19. Imaki J, Mae Y, Shimizu S, Ohno Y. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett, 2009; 454: 143-147.
20. Gower AJ and Tricklebank MD. Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonfilict test in the rat. Eur J Pharmacol, 1988; 155: 129-137.
21. Jadhav SA, Gaikwad RV, Gaonkar RK, Thorat VM, Gursale SC, Balsara JJ. Dose-dependent response of central dopaminergic systems to buspirone in mice. Indian J Exp Biol, 2008, 46: 704-714.
22. Harrington MA, Oksenberg D, Peroutka SJ. 5-Hydroxytryptamine 1A receptors are linked to a Gi-adenylate cyclase complex in rat hippocampus. Eur J Pharmacol, 1988; 154: 95-98.
23. Dilsaver SC, Benazzi F, Akiskal KK, Akiskal HS. Differential patterns of lifetime multiple anxiety disorder comorbidity between Latino adults with bipolar I and major depressive disorders. Bull Menninger Clin, 2008; 72: 130-148.